| Baudax Bio is a pharmaceutical company primarily focused on developing and commercializing products for hospital and related acute care settings. Co.'s main product candidate is a proprietary injectable form of meloxicam, a once a day, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. Co.'s other early-stage product candidates include; intermediate and short-acting neuromuscular blocking agents, which are used as muscle paralyzing agents to facilitate intubation and surgery; and accompanying reversal agents, DEX-IN, which is a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties. We show 8 historical shares outstanding datapoints in our BXRX shares outstanding history coverage, used to compute BXRX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BXRX market cap history over the course of time is important for investors
interested in comparing BXRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BXRX versus a peer is one thing; comparing
BXRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BXRX can fluctuate over the course of history.
With this page we aim to empower investors researching BXRX by allowing them to research the BXRX market cap history.